The close of the funding round builds on recent milestones the company has achieved, including receiving $ 4 million in NIH grant funding, completing the Cedars-Sinai Accelerator program and initiating their pivotal FDA study. The profits will be used to prepare for the commercial launch in 2022 of FlowSense ™, the company’s first product.
“Anna lisa somera and dr. John rogers are prolific leaders in the Chicago life science ecosystem. Along with the rest of the Rhaeos team, they have the ability and expertise to commercialize the FlowSense ™ platform to help improve the lives of millions of patients with hydrocephalus and other chronic diseases. conditions, “ noted Jean Flavin, founder and CEO of Portal Innovations.
About Rhaeos, Inc.
Rhaeos, Inc. is a privately-held clinical-stage medical device company formed by award-winning research group John A. Rogers at Northwestern University focused on the development of wearable sensors to improve the care of patients with chronic and difficult-to-disease conditions. – treat ailments. The company’s new non-invasive FlowSense ™ wireless sensor addresses an unmet clinical need in patients with hydrocephalus and is funded by the National Institute of Health, National Science Foundation, Pediatric Hydrocephalus Foundation, Southwest Pediatric Device Consortium , the National Capital Consortium for Pediatric Device Innovation, the UCSF-Stanford Pediatric Device Accelerator, the West Coast Consortium for Pediatric Technology and Innovation, MedTech Innovator, and private and institutional investors.
About Creative Ventures
Creative Ventures is a method-oriented venture capital firm focused on investing in early stage, deep technology companies. With a market-first principle, Creative Ventures leverages its deep technical and managerial expertise to help businesses cope with labor shortages, climate change and rising healthcare costs. health.
About the Innovations Portal
Portal Innovations is a leading business development engine that connects scientific ideation in life sciences, medical technologies and bioinformatics innovation through business proof of concept by providing seed capital, fully equipped laboratory space and management expertise to high potential early stage businesses tackling underserved human health issues.
SOURCE Rhaeos, Inc.